About Prolaio
Prolaio is a company based in Jacksonville (United States) founded in 2021 was acquired by Kardigan in March 2025. Prolaio has raised $25.5 million across 1 funding round from investors including Kardigan. Prolaio offers products and services including Prolaio Platform and FDA-Cleared Algorithms. Prolaio operates in a competitive market with competitors including WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus, among others.
- Headquarter Jacksonville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Prolaio
Prolaio offers a comprehensive portfolio of products and services, including Prolaio Platform and FDA-Cleared Algorithms.
Secure platform for remote heart health data collection and analysis.
Algorithms that predict cardiovascular conditions for better clinical decisions.
People of Prolaio
Unlock access to complete
Funding Insights of Prolaio
Prolaio has successfully raised a total of $25.5M through 1 strategic funding round. The most recent funding activity was a Series B round of $25.5 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Prolaio
Prolaio has secured backing from 1 investor. Prominent investors backing the company include Kardigan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech company developing personalized medicines for cardiovascular diseases
|
Locked | Locked | Locked |
Investor details for Prolaio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prolaio
Investment portfolio details for Prolaio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prolaio
Detailed financials for Prolaio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prolaio Comparisons
Peer comparison for Prolaio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prolaio
Prolaio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of CRO and CDMO services
|
|
| Locked | Locked | Locked |
Laboratory testing and contract research services are provided globally.
|
|
| Locked | Locked | Locked |
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
|
|
| Locked | Locked | Locked |
Branded and generic prescription drugs are developed, manufactured, and marketed.
|
|
| Locked | Locked | Locked |
Advisory, scientific, and medical communications provided for pharmaceutical industry.
|
|
| Locked | Locked | Locked |
Regulatory support, brand differentiation, and prototyping services are provided.
|
Detailed competitors of Prolaio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prolaio
Complete news archive for Prolaio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prolaio
Prolaio was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Prolaio is headquartered in Jacksonville, United States.
Prolaio is a funded company, having raised a total of $25.5M across 1 funding round to date.
Company offers prescriptive analytics for pharmaceutical Industry. It utilize data science and biomarkers to develop solutions for pharmaceutical.
Prolaio's top competitors include WuXi AppTec, ANI Pharmaceuticals and Aptar.
Prolaio offers Prolaio Platform and FDA-Cleared Algorithms.
Prolaio has 1 investor. Key investors include Kardigan.